Sánchez Connie
H. Lundbeck A/S, Neuropharmacological Research, Ottiliavej 9, DK-2500 Valby, Copenhagen, Denmark.
Basic Clin Pharmacol Toxicol. 2006 Aug;99(2):91-5. doi: 10.1111/j.1742-7843.2006.pto_295.x.
Recent results on the in vivo and in vitro pharmacology of escitalopram are summarised. The exact molecular mechanism by which R-citalopram inhibits the effect of S-citalopram on the serotonin transporter remains to be elucidated. Preliminary evidence indicates an effect of R-citalopram on the association of escitalopram with the high affinity primary site, and on its dissociation from the serotonin transporter, via an allosteric mechanism. Escitalopram can be considered as an allosteric serotonin reuptake inhibitor. This serotonin dual action in binding to two sites on the serotonin transporter (both the primary site and the allosteric site) is hypothesised to be responsible for a longer binding to, and therefore greater inhibition of the serotonin transporter by escitalopram.
本文总结了艾司西酞普兰体内和体外药理学的最新研究结果。R-西酞普兰抑制S-西酞普兰对5-羟色胺转运体作用的确切分子机制仍有待阐明。初步证据表明,R-西酞普兰通过变构机制对艾司西酞普兰与高亲和力主要位点的结合及其从5-羟色胺转运体的解离产生影响。艾司西酞普兰可被视为变构5-羟色胺再摄取抑制剂。据推测,这种在5-羟色胺转运体上两个位点(主要位点和变构位点)的双重结合作用,使得艾司西酞普兰与5-羟色胺转运体的结合时间更长,从而对其抑制作用更强。